BioClinica Announces eHealth App xChange
NEWTOWN, Pa., Sept. 2, 2015 – BioClinica®, Inc., a specialty clinical trials technology and services provider today announced the creation of the eHealth App xChangeTM, an alliance channel for disruptive technology innovation across life sciences and healthcare. BioClinica’s eHealth App xChange provides healthcare payers, providers, researchers, regulators and patients with access to transformative applications integrated with and delivered through BioClinica’s eHealth Cloud™.
The App xChange is a key component of the expanding BioClinica Partner Alliance program, a strategic priority led by eClinical President Mukhtar Ahmed. “BioClinica has a culture of innovation within clinical research,” said Ahmed. “BioClinica’s eHealth App xChange enables research communities to leverage an ecosystem of integrated mobile and cloud applications for unique patient and consumer engagement, digital medicine, biosensor and scientific analytic capabilities, thereby accelerating pre- and post-approval research while creating efficiency and quality benefits.”
Ahmed explained, “Our approach introduces pragmatic industry innovation and provides our customers with an integrated and highly interoperable platform that extends across the entire healthcare research landscape.”
BioClinica Global Product Development Senior Vice President Andrew Masters said, “Healthcare research applications like these are a natural fit with our core products and extend the BioClinica platform with source data capture, point of care, electronic patient record, workflow and safety offerings.” Masters added, “Our App xChange is an incubator and growth engine for niche technology providers and individual app developers, and we welcome new partners as BioClinica continues to lead industry innovation within the regulated clinical trial space.”
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
AbbVie Submits sNDA to FDA for Venclexta-Acalabrutinib Combo in Frontline CLL
July 29th 2025The application is backed by Phase III AMPLIFY trial results showing the oral combination significantly improved progression-free survival versus chemoimmunotherapy in previously untreated chronic lymphocytic leukemia.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
J&J Submits sBLA to FDA for Tremfya Label Expansion Based on PsA Joint Damage Inhibition Data
July 29th 2025The submission is supported by Phase IIIb APEX trial results showing Tremfya reduced symptoms and inhibited structural progression in biologic-naïve patients with active psoriatic arthritis.
